Krystal Biotech
KRYS
324.57
-2.24
-0.69%
Krystal Biotech
US · KRYS
#1515 by market cap
Listed 2017
324.57
-2.24
-0.69%
Live - 5344 symbols - heartbeat 303s ago
· 2026-10-08 05:56
Pre-market
324.57
0.00%
After-hours
324.57
0.00%
- Market cap
- 9.61B
- P/E (TTM)i
- 40.67
- P/Bi
- 7.07
- EPSi
- 6.84
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KRYS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 52.00, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +33.94% YoY
Margins
- Gross margin
- 94.08%
- Operating margin
- 41.45%
- Net margin
- 52.64%
Key ratios & quality
- Altman Z-Scorei
- 52.00
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0 | 0 | 50.70M | 290.52M | 389.13M |
| Gross profit | -- | -- | -- | 0 | 0 | 47.61M | 270.45M | 366.08M |
| Selling & admin expenses | 4.16M | 6.47M | 15.06M | 40.39M | 77.74M | 98.29M | 113.63M | 146.74M |
| Research & development | 7.76M | 15.62M | 17.94M | 27.88M | 42.46M | 46.43M | 53.58M | 58.05M |
| Operating profit | -11.92M | -22.08M | -33.00M | -68.28M | -120.20M | -97.12M | 103.25M | 161.30M |
| Pretax profit | -10.89M | -19.09M | -32.17M | -69.57M | -139.98M | 12.90M | 95.36M | 189.47M |
| Tax | -- | -- | -- | 0 | 0 | 1.97M | 6.20M | -15.36M |
| Net profit | -10.89M | -19.09M | -32.17M | -69.57M | -139.98M | 10.93M | 89.16M | 204.83M |
| Basic EPS | -1 | -1 | -2 | -3 | -5 | 0 | 3 | 7 |
| Diluted EPS | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 88.18M | 96.04M | 97.80M | 107.11M | 116.36M | 119.22M |
| Gross profit | 83.16M | 88.88M | 93.54M | 100.51M | 110.03M | 112.79M |
| Selling & admin expenses | 32.65M | 35.07M | 37.58M | 41.45M | 41.01M | 39.85M |
| Research & development | 14.26M | 14.41M | 14.59M | 14.79M | 15.33M | 14.52M |
| Operating profit | 36.25M | 39.40M | 41.37M | 44.27M | 53.69M | 58.42M |
| Pretax profit | 43.60M | 46.78M | 47.97M | 51.13M | 61.44M | 66.08M |
| Tax | 7.86M | 8.44M | -31.40M | -269.00K | 5.51M | 11.31M |
| Net profit | 35.73M | 38.33M | 79.37M | 51.40M | 55.93M | 54.77M |
| Basic EPS | 1 | 1 | 3 | 2 | 2 | 2 |
| Diluted EPS | 1.20 | 1.29 | 2.66 | 1.70 | 1.83 | 1.79 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 112.65M | 195.88M | 275.06M | 442.27M | 383.78M | 587.91M | 742.05M | 1.02B |
| Cash & ST investments | 111.76M | 193.69M | 271.26M | 438.10M | 379.17M | 532.18M | 597.52M | 827.79M |
| Inventory | -- | -- | -- | -- | 0 | 6.99M | 26.51M | 40.48M |
| Total assets | 116.12M | 209.02M | 310.84M | 626.30M | 558.45M | 818.36M | 1.06B | 1.33B |
| Total current liabilities | 2.60M | 3.33M | 15.45M | 25.74M | 28.85M | 33.09M | 102.00M | 102.94M |
| Short-term debt | -- | 480.00K | 8.24M | 1.04M | 1.56M | 1.47M | 1.22M | 1.77M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 2,890,000.00 | 6,109,000.00 | 18,760,000.00 | 32,719,000.00 | 36,219,000.00 | 39,714,000.00 | 109,458,000.00 | 114,234,000.00 |
| Total equity | 113.23M | 202.91M | 292.08M | 593.58M | 522.23M | 778.64M | 946.38M | 1.22B |
| Retained earnings | -19.96M | -39.05M | -71.21M | -140.78M | -280.76M | -269.83M | -180.67M | 24.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 766.80M | 841.35M | 925.65M | 1.02B | 1.02B | 1.06B |
| Cash & ST investments | 616.85M | 681.99M | 731.07M | 827.79M | 823.41M | 845.63M |
| Inventory | 29.94M | 31.04M | 37.63M | 40.48M | 42.65M | 45.56M |
| Total assets | 1.07B | 1.14B | 1.24B | 1.33B | 1.40B | 1.50B |
| Total current liabilities | 79.49M | 86.90M | 91.27M | 102.94M | 107.80M | 127.40M |
| Short-term debt | 1.36M | 1.62M | 1.70M | 1.77M | 1.80M | 1.81M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 89,742,000.00 | 97,747,000.00 | 102,218,000.00 | 114,234,000.00 | 120,238,000.00 | 141,522,000.00 |
| Total equity | 984.67M | 1.04B | 1.14B | 1.22B | 1.28B | 1.36B |
| Retained earnings | -144.94M | -106.60M | -27.24M | 24.16M | 80.10M | 134.86M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.45M | -18.69M | -26.08M | -47.94M | -100.57M | -88.80M | 123.42M | 200.87M |
| Depreciation & amortization | 141.00K | 1.09M | 1.85M | 1.85M | 3.39M | 5.91M | 6.71M | 6.55M |
| Free cash flow | -11.68M | -25.09M | -40.93M | -116.27M | -153.55M | -100.60M | 119.18M | 188.91M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 73.85M | 107.53M | 118.02M | 355.65M | 28.99M | 159.73M | 0 | 0 |
| Ending cash balance | 103.67M | 187.51M | 268.27M | 341.25M | 161.90M | 358.33M | 344.87M | 496.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 30.97M | 52.73M | 39.66M | 77.51M | 80.38M | 74.79M |
| Depreciation & amortization | 1.63M | 1.54M | 1.61M | 1.76M | 1.73M | 1.57M |
| Free cash flow | 24.77M | 50.83M | 37.96M | 75.37M | 73.23M | 71.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 308.77M | 353.83M | 392.60M | 496.30M | 501.31M | 427.74M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -13.39 | -12.08 | -13.00 | -15.71 | -25.09 | 1.68 | 10.34 | 18.91 |
| ROA %i | -13.10 | -11.74 | -12.38 | -14.85 | -23.63 | 1.59 | 9.51 | 17.14 |
| ROIC %i | -13.39 | -11.83 | -12.95 | -15.08 | -25.64 | -1.25 | 7.06 | 16.73 |
| 5-year avg ROE %i | -- | -- | -- | -17.38 | -15.85 | -12.84 | -8.36 | -1.97 |
| EBIT margin %i | -- | -- | -- | -- | -- | 25.44 | 35.52 | 41.45 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 41.02 | 48.55 |
| Current ratioi | 43.39 | 58.88 | 17.80 | 17.18 | 13.30 | 17.76 | 7.28 | 9.95 |
| Quick ratioi | 43.05 | 58.22 | 17.56 | 17.02 | 13.14 | 17.35 | 6.89 | 9.28 |
| Debt / assetsi | 0.00 | 1.56 | 3.71 | 1.28 | 1.60 | 0.99 | 0.69 | 0.70 |
| LT debt / equityi | -- | 1.37 | 1.13 | 1.18 | 1.41 | 0.85 | 0.64 | 0.62 |
| Interest coveragei | -- | -- | -- | -45.63 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 0.00 | 0.00 | 0.00 | 0.00 | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 13.90 | 15.61 | 19.66 | 18.91 | 19.90 | 20.12 |
| ROA %i | 12.86 | 14.27 | 17.90 | 17.14 | 18.21 | 18.30 |
| ROIC %i | 13.76 | 12.77 | 17.28 | 16.73 | 19.74 | 18.54 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 40.05 | 42.26 | 42.43 | 41.45 | 42.83 | 44.89 |
| FCF / sales %i | 38.78 | 51.63 | 44.37 | 48.55 | 56.88 | 58.52 |
| Current ratioi | 9.65 | 9.68 | 10.14 | 9.95 | 9.46 | 8.32 |
| Quick ratioi | 9.06 | 9.13 | 9.43 | 9.28 | 8.82 | 7.73 |
| Debt / assetsi | 0.90 | 0.85 | 0.77 | 0.70 | 0.65 | 0.59 |
| LT debt / equityi | 0.84 | 0.77 | 0.69 | 0.62 | 0.57 | 0.52 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-08 05:56:28 · For reference only, not investment advice and not tailored to your situation.